Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
Clinical trial NCT04337658 · UNKNOWN
Trial details
- NCT number
- NCT04337658
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-01
- Primary completion
- 2024-04-30
- Enrollment
- 493
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.